Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 6/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | UBE2N | P61088 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856058 | 0.86 | KDM4E (0.47) | MAPK1NPSR1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL248004 | 0.82 | ESR1 (0.44) | MAPK1NPSR1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL9083094 | 0.80 | MAPK1 (0.64) | MAPK1NPSR1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL7456145 | 0.80 | THRA (0.54) | MAPK1NPSR1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL799537 | 0.79 | MAPK1 (0.50) | MAPK1NPSR1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL10223630 | 0.79 | KDM4E (0.50) | MAPK1NPSR1SMN1; SMN2MAPTGLA | |
| SCHEMBL799834 | 0.79 | ESR1 (0.46) | MAPK1NPSR1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL4801925 | 0.78 | KDM4E (0.46) | MAPK1NPSR1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL799638 | 0.78 | MAPT (0.43) | MAPK1NPSR1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL4623886 | 0.78 | ESR1 (0.40) | MAPK1NPSR1SMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327456-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-11-16 | — | — | US | disclosed |
| EP-2821400-B1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9751839-B2 | Process for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170096396-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-06 | — | — | US | disclosed |
| US-20160221952-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-04 | — | — | US | disclosed |
| US-9371287-B2 | Process for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150315151-A2 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-05 | — | — | US | disclosed |
| EP-2408750-B1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20150073015-A2 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2015-03-12 | — | — | US | disclosed |
| EP-2821400-A1 | Process for making modulators of cystic fibrosis transmembrane conductance regulator | Vertex Pharmaceuticals Incorporated (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20140228400-A2 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED | 2014-08-14 | — | — | US | disclosed |
| US-8796308-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARAMACEUTICALS INCORPORATED (US) | 2014-08-05 | — | — | US | disclosed |
| US-8765957-B2 | Process for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140088142-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140012003-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-09 | — | — | US | disclosed |
| US-8476442-B2 | Process for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130072522-A1 | Process for Making Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120122921-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120071504-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100267768-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327456-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | MAPK1 1708/4885NPSR1 2487/4885SMN1; SMN2 4816/4885 |
| US-20140012003-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | MAPK1 1708/4885NPSR1 2487/4885SMN1; SMN2 4816/4885 |
| US-20130072522-A1 | Process for Making Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SLC26A4, TMEM109 | MAPK1 1708/4885NPSR1 2487/4885SMN1; SMN2 4816/4885 |
| US-20100267768-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | MAPK1 1708/4885NPSR1 2487/4885SMN1; SMN2 4816/4885 |
| US-20150073015-A2 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | MAPK1 1708/4885NPSR1 2487/4885SMN1; SMN2 4816/4885 |
| US-20140088142-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, CLCN2 | MAPK1 2184/4885NPSR1 2267/4885SMN1; SMN2 4842/4885 |
| US-20170096396-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | MAPK1 1708/4885NPSR1 2487/4885SMN1; SMN2 4816/4885 |
| US-20120122921-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | MAPK1 1708/4885NPSR1 2487/4885SMN1; SMN2 4816/4885 |
| US-20160221952-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, CLCN2 | MAPK1 2184/4885NPSR1 2267/4885SMN1; SMN2 4842/4885 |
| US-20150315151-A2 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | MAPK1 1708/4885NPSR1 2487/4885SMN1; SMN2 4816/4885 |
| US-20140228400-A2 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1B, CLCN2 | MAPK1 2184/4885NPSR1 2267/4885SMN1; SMN2 4842/4885 |
| US-20120071504-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, CLCN2 | MAPK1 2184/4885NPSR1 2267/4885SMN1; SMN2 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.